Biotest Aktiengesellschaft (BIO3) - Net Assets

Latest as of March 2025: €509.60 Million EUR ≈ $595.78 Million USD

Based on the latest financial reports, Biotest Aktiengesellschaft (BIO3) has net assets worth €509.60 Million EUR (≈ $595.78 Million USD) as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.42 Billion ≈ $1.66 Billion USD) and total liabilities (€906.90 Million ≈ $1.06 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Biotest Aktiengesellschaft PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€509.60 Million
% of Total Assets	35.98%
Annual Growth Rate	7.38%
5-Year Change	20.18%
10-Year Change	28.72%
Growth Volatility	18.04

Biotest Aktiengesellschaft - Net Assets Trend (2002–2024)

This chart illustrates how Biotest Aktiengesellschaft's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see BIO3 market cap overview.

Annual Net Assets for Biotest Aktiengesellschaft (2002–2024)

The table below shows the annual net assets of Biotest Aktiengesellschaft from 2002 to 2024. Also explore net asset growth rate of Biotest Aktiengesellschaft to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2024-12-31	€530.70 Million ≈ $620.44 Million	+6.37%
2023-12-31	€498.90 Million ≈ $583.27 Million	+34.44%
2022-12-31	€371.10 Million ≈ $433.85 Million	-2.44%
2021-12-31	€380.40 Million ≈ $444.73 Million	-13.86%
2020-12-31	€441.60 Million ≈ $516.28 Million	-7.40%
2019-12-31	€476.90 Million ≈ $557.55 Million	-3.70%
2018-12-31	€495.20 Million ≈ $578.94 Million	+42.38%
2017-12-31	€347.80 Million ≈ $406.61 Million	-3.58%
2016-12-31	€360.70 Million ≈ $421.70 Million	-12.52%
2015-12-31	€412.30 Million ≈ $482.02 Million	-14.14%
2014-12-31	€480.20 Million ≈ $561.40 Million	+4.23%
2013-12-31	€460.70 Million ≈ $538.61 Million	+24.70%
2012-12-31	€369.43 Million ≈ $431.91 Million	+6.57%
2011-12-31	€346.67 Million ≈ $405.29 Million	+12.70%
2010-12-31	€307.61 Million ≈ $359.63 Million	+13.99%
2009-12-31	€269.86 Million ≈ $315.50 Million	+6.51%
2008-12-31	€253.37 Million ≈ $296.22 Million	+12.23%
2007-12-31	€225.76 Million ≈ $263.94 Million	+25.90%
2006-12-31	€179.31 Million ≈ $209.64 Million	+6.12%
2005-12-31	€168.97 Million ≈ $197.55 Million	+56.51%
2004-12-31	€107.97 Million ≈ $126.22 Million	+4.53%
2003-12-31	€103.29 Million ≈ $120.75 Million	-6.78%
2002-12-31	€110.79 Million ≈ $129.53 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Biotest Aktiengesellschaft's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 27450000000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	€274.50 Million	51.72%
Common Stock	€39.60 Million	7.46%
Other Components	€216.60 Million	40.81%
Total Equity	€530.70 Million	100.00%

Biotest Aktiengesellschaft Competitors by Market Cap

The table below lists competitors of Biotest Aktiengesellschaft ranked by their market capitalization.

Company	Market Cap
Liberty Broadband Srs A NASDAQ:LBRDA	$656.99 Million
Ballard Power Systems Inc TO:BLDP	$657.00 Million
Hunan Airbluer Environmental Protection Technology Co. Ltd. SHE:301259	$657.04 Million
King-Strong New Material Technology Co Ltd SHE:300629	$657.09 Million
Shanghai Kelai Mechatronics SHG:603960	$656.86 Million
Chapters Group AG XETRA:CHG	$656.80 Million
ACNB Corporation NASDAQ:ACNB	$656.67 Million
Mengtian Home Group Inc. SHG:603216	$656.62 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Biotest Aktiengesellschaft's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 498,900,000 to 530,700,000, a change of 31,800,000 (6.4%).
Net income of 26,400,000 contributed positively to equity growth.
Dividend payments of 1,600,000 reduced retained earnings.
Other comprehensive income decreased equity by 1,100,000.
Other factors increased equity by 8,100,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	€26.40 Million	+4.97%
Dividends Paid	€1.60 Million	-0.3%
Other Comprehensive Income	€-1.10 Million	-0.21%
Other Changes	€8.10 Million	+1.53%
Total Change	€-	6.37%

Book Value vs Market Value Analysis

This analysis compares Biotest Aktiengesellschaft's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.12x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 6.42x to 2.12x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2002-12-31	€4.43	€28.40	x
2003-12-31	€4.18	€28.40	x
2004-12-31	€4.34	€28.40	x
2005-12-31	€6.33	€28.40	x
2006-12-31	€5.52	€28.40	x
2007-12-31	€6.78	€28.40	x
2008-12-31	€7.07	€28.40	x
2009-12-31	€7.52	€28.40	x
2010-12-31	€8.57	€28.40	x
2011-12-31	€9.85	€28.40	x
2012-12-31	€10.50	€28.40	x
2013-12-31	€12.32	€28.40	x
2014-12-31	€12.13	€28.40	x
2015-12-31	€10.42	€28.40	x
2016-12-31	€9.11	€28.40	x
2017-12-31	€8.78	€28.40	x
2018-12-31	€12.51	€28.40	x
2019-12-31	€12.05	€28.40	x
2020-12-31	€11.16	€28.40	x
2021-12-31	€9.61	€28.40	x
2022-12-31	€9.38	€28.40	x
2023-12-31	€12.61	€28.40	x
2024-12-31	€13.41	€28.40	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Biotest Aktiengesellschaft utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 4.97%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 3.64%
• Asset Turnover: 0.51x
• Equity Multiplier: 2.70x
Recent ROE (4.97%) is above the historical average (4.56%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2002	18.64%	7.68%	0.69x	3.50x	€9.18 Million
2003	-5.22%	-2.36%	0.63x	3.49x	€-15.29 Million
2004	5.62%	2.69%	0.61x	3.44x	€-4.55 Million
2007	7.77%	5.29%	0.61x	2.41x	€-4.97 Million
2008	11.30%	7.29%	0.65x	2.38x	€3.23 Million
2009	10.58%	7.18%	0.62x	2.39x	€1.54 Million
2010	13.09%	9.57%	0.65x	2.10x	€9.33 Million
2011	13.89%	11.41%	0.62x	1.97x	€13.49 Million
2012	9.05%	7.59%	0.64x	1.85x	€-3.52 Million
2013	6.95%	6.39%	0.56x	1.92x	€-14.06 Million
2014	4.00%	3.30%	0.56x	2.15x	€-28.81 Million
2015	-20.01%	-13.99%	0.61x	2.34x	€-123.72 Million
2016	-12.70%	-8.28%	0.59x	2.59x	€-81.85 Million
2017	-1.01%	-0.93%	0.39x	2.82x	€-38.26 Million
2018	36.71%	45.39%	0.38x	2.11x	€132.20 Million
2019	-0.99%	-1.12%	0.38x	2.32x	€-52.39 Million
2020	-7.11%	-6.48%	0.43x	2.56x	€-75.56 Million
2021	-16.67%	-12.30%	0.47x	2.90x	€-101.44 Million
2022	-8.54%	-6.14%	0.43x	3.24x	€-68.81 Million
2023	25.46%	18.55%	0.49x	2.83x	€77.11 Million
2024	4.97%	3.64%	0.51x	2.70x	€-26.67 Million

Industry Comparison

This section compares Biotest Aktiengesellschaft's net assets metrics with peer companies in the same industry.

Industry Context

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Biotest Aktiengesellschaft (BIO3)	€509.60 Million	18.64%	1.78x	$656.94 Million
Covestro AG (1COV)	$5.25 Billion	10.51%	1.19x	$11.10 Billion
CENTESSA PHARMACEUTICALS (260)	$401.55 Million	-58.71%	0.44x	$5.35 Billion
2invest AG (2INV)	$82.98 Million	26.70%	0.01x	$70.69 Million
COINSHARES I. LS-000247 (3TW)	$393.95 Million	33.24%	14.29x	$472.53 Million
Adaptimmune Therapeutics plc (473A)	$166.14 Million	-43.08%	0.41x	$42.94 Million
KINGMAN MINERALS LTD. (47A)	$1.44 Million	-21.74%	0.28x	$178.38K
GENOR BIOPHARMA DL-00002 (67N0)	$1.19 Billion	-56.64%	0.22x	$93.97 Million
BENO Holding AG (BENH)	$30.09 Million	13.51%	2.23x	$75.57K
Biotest Aktiengesellschaft (BIO)	$380.40 Million	-16.67%	1.90x	$976.15 Million

About Biotest Aktiengesellschaft

XETRA:BIO3 Germany

Market Cap

$656.94 Million

€561.91 Million EUR

Market Cap Rank

#10969 Global

#1260 in Germany

Share Price

€28.40

Change (1 day)

+0.00%

52-Week Range

€28.40 - €28.40

All Time High

€43.69